Nanotechnology in Pharmacotherapy: Targeted Approaches for Enhanced Drug Delivery

Description

One of the key advantages of micro molecular drug delivery is its ability to overcome the limitations of traditional drug delivery systems. Conventional methods often result in poor drug solubility, limited bioavailability, and nonspecific distribution within the body, leading to suboptimal therapeutic outcomes and potential side effects. In contrast, micro molecular drug delivery techniques enable the design of drug carriers with precisely controlled size, shape, and surface properties, allowing for enhanced drug stability, solubility, and targeted delivery to diseased tissues or cells [1-5]. Nanotechnology plays a central role in micro molecular drug delivery, offering a range of nanocarrier platforms such as liposomes, nanoparticles, dendrimers, and micelles [6]. These nanocarriers can be functionalized with targeting ligands, antibodies, or peptides to selectively bind to receptors or antigens overexpressed on the surface of diseased cells, thereby facilitating site-specific drug delivery and reducing off-target effects. Additionally, the small size of these carriers enables them to penetrate biological barriers such as the blood-brain barrier, enhancing drug delivery to previously inaccessible sites [7-9].

Furthermore, micro molecular drug delivery enables the controlled release of therapeutic agents over time, allowing for sustained drug concentrations at the target site and minimizing the need for frequent dosing. This controlled release can be achieved through various mechanisms, including diffusion, degradation, and stimulus-responsive drug release triggered by environmental factors such as pH, temperature, or enzyme activity [10].

However, despite its tremendous potential, micro molecular drug delivery faces several challenges that must be addressed to realize its full clinical impact. These include concerns regarding the biocompatibility, stability, and scalability of nano carrier systems, as well as the potential for immune responses and toxicity associated with long-term exposure to nanomaterials [11]. Additionally, regulatory hurdles and manufacturing complexities may hinder the translation of micro molecular drug delivery technologies from the laboratory to the clinic.

Micro molecular drug delivery represents a paradigm shift in drug delivery strategies, offering unprecedented precision, targeting, and control over therapeutic interventions. While significant challenges remain, ongoing research and innovation in this field hold the promise of transforming the treatment of a wide range of diseases, from cancer and infectious diseases to neurological disorders and chronic conditions [12-14].

Micro molecular drug delivery has revolutionized pharmacotherapy by offering targeted and precise delivery of therapeutic agents. Utilizing nanotechnology, drug carriers can be engineered with remarkable specificity, enabling them to navigate biological barriers and reach their intended targets with unprecedented accuracy. This level of precision not only enhances therapeutic efficacy but also minimizes off-target effects and systemic toxicity. Additionally, micro molecular drug delivery holds immense potential for personalized medicine, as it allows for the customization of drug formulations based on individual patient characteristics. Despite remaining challenges, the continued advancement of this field promises to usher in a new era of safer, more effective drug therapies.

Micro molecular drug delivery promises targeted precision, navigating biological barriers with accuracy for optimal therapeutic outcomes. Its potential extends to personalized medicine, tailoring drug formulations to individual patient needs [15]. Despite challenges, advancements hold promise for safer, more effective therapies.

References

1. Shi J, et al. Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer. 2016; 17:2-3.

   [Crossref] [Google Scholar] [Pubmed]

2. Cabral H, et al. Supramolecularnanodevices: From design validation to theranosticnanomedicine. Acc Chem Res.  2011;44:999-1008.

   [Crossref] [Google Scholar] [Pubmed]

3. Thanou M, et al. Polymer-protein and polymer-drug conjugates in cancer therapy. Curr Opin Investig Drugs. 2003;4:701-709. 

   [Google Scholar] [Pubmed]

4. Shi JJ, et al. Self-assembled targeted nanoparticles Evolution of technologies and bench to bedside translation. Acc Chem Res. 2011;44:1123-1134.

   [Crossref] [Google Scholar] [Pubmed]

5. Park DH, et al. Biodegradable inorganic nanovector: Passive versus active tumor targeting in siRNA transportation. Angew Chem Int Ed. 2016;55: 4582–4586.

   [Crossref] [Google Scholar] [Pubmed]

6. Jin YZ, et al. Core-shell nanocarriers with high paclitaxel loading for passive and active targeting. Sci Rep UK.  2016;6:1-6.

   [Crossref] [Google Scholar] [Pubmed]

7. Guo Y, et al. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol Lett. 2015;9: 1065–1072.

   [Crossref] [Google Scholar] [Pubmed]

8. Liu GD, et al. PEG-PLGA Nanoparticle modified by Transferrin Loading Doxorubicin: In vitro and in vivo Studies for glioma. Adv Mater Res. 2013;750–752:1643–1650.

   [Crossref] [Google Scholar] [Pubmed]

9. Hrkach J, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4:128-139.

   [Crossref] [Google Scholar] [Pubmed]

10. Peter AJ, et al. Targeting the cancer epigenome for therapy. Nat Rev Geneti. 2016;17: 630-636.

    [Crossref] [Google Scholar] [Pubmed]

11. Shin WK, et al.   Cross-linked composite gel polymer electrolyte using mesoporous methacrylate-functionalized SiO2 nanoparticles for lithium-ion polymer batteries. Sci rep. 2016;6:263-268.

    [Crossref] [Google Scholar] [Pubmed]

12. Daglioglu C, et al. Environmentally responsive dual-targeting nanoparticles: improving drug accumulation in cancer cells as a way of preventing anticancer drug efflux.  J Pharm Sci. 2018;107:934-941.

    [Crossref] [Google Scholar] [Pubmed]

13. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58:1532-1555.

    [Crossref] [Google Scholar] [Pubmed]

14. Xia Y, et al. pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells. Colloids Surf B Biointerfaces. 2018;170:514-520.

    [Crossref] [Google Scholar] [Pubmed]

15. Chittasupho C, et al. CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition. Eur J Pharm Biopharm. 2017;119:310-321.

    [Crossref] [Google Scholar] [Pubmed]